Tarsus Pharmaceuticals 

Yahoo Finance • 13 days ago

Interesting TARS Put And Call Options For November 21st

Investors in Tarsus Pharmaceuticals Inc (Symbol: TARS) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TARS options chain for the new... Full story

Yahoo Finance • last month

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20th Annual Healthcare Confe... Full story

Yahoo Finance • 2 months ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q2 2025 MANAGEMENT VIEW * CEO Bobak R. Azamian highlighted that "we delivered record-breaking results of more than $100 million in net sales and approximately 91,000 bottles dispens... Full story

Yahoo Finance • 2 months ago

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and le... Full story

Yahoo Finance • 2 months ago

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 202... Full story

Yahoo Finance • 5 months ago

Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) stands against other best breakout stocks to buy accordi... Full story

Yahoo Finance • 5 months ago

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the i... Full story

Yahoo Finance • 7 months ago

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at... Full story

Yahoo Finance • 7 months ago

Tarsus Announces Proposed $100.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stoc... Full story

Yahoo Finance • 7 months ago

Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the Barclays 27th Annual Global Healthcare Conference on Tuesday, Marc... Full story

Yahoo Finance • 7 months ago

Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025

IRVINE, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Tuesday, February 25, 2025, to report its fourth quarter an... Full story

Yahoo Finance • 2 years ago

11 Stocks That Will Make You Rich in 5-10 Years

In this article, we will take a detailed look at the11 Stocks That Will Make You Rich in 5-10 Years. For a quick overview of such stocks, read our article 5Stocks That Will Make You Rich in 5-10 Years. Can investing in stocks make you ric... Full story

Yahoo Finance • 2 years ago

Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements

Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 mill... Full story

Yahoo Finance • 2 years ago

Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • 2 years ago

Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis

IRVINE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with e... Full story

Yahoo Finance • 2 years ago

Tarsus to Present at Upcoming Investor Conferences

IRVINE, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • 2 years ago

Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis

Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available via prescription from an eye care provi... Full story

Yahoo Finance • 2 years ago

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

IRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with ey... Full story

Yahoo Finance • 2 years ago

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye... Full story